No Data
No Data
New Analyst Forecast: $GRAL Given $32.0 Price Target
GRAIL to Present New Data on Galleri and Its Methylation Platform at American Association for Cancer Research (AACR) Annual Meeting
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
CCORF Initiates Grail(GRAL.US) With Buy Rating, Announces Target Price $32
This Cancer Test Could Become Routine -- and a Big Seller, Says Analyst -- Barrons.com
Express News | Canaccord Genuity Initiates Coverage On GRAIL With Buy Rating, Announces Price Target of $32